SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration.

Pembrey, L; Barreto, ML; Douwes, J; Cooper, P; Henderson, J; Mpairwe, H; Ardura-Garcia, C; Chico, M; Brooks, C; Cruz, AA; et al. Pembrey, L; Barreto, ML; Douwes, J; Cooper, P; Henderson, J; Mpairwe, H; Ardura-Garcia, C; Chico, M; Brooks, C; Cruz, AA; Elliott, AM; Figueiredo, CA; Langan, SM; Nassanga, B; Ring, S; Rodrigues, L; Pearce, N (2018) Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration. ERJ Open Res, 4 (3). 00013-2018. ISSN 2312-0541 https://doi.org/10.1183/23120541.00013-2018
SGUL Authors: Cooper, Philip John

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (343kB) | Preview

Abstract

The World Asthma Phenotypes (WASP) study started in 2016 and has been conducted in five centres, in the UK, New Zealand, Brazil, Ecuador and Uganda. The objectives of this study are to combine detailed biomarker and clinical information in order to 1) better understand and characterise asthma phenotypes in high-income countries (HICs) and low and middle-income countries (LMICs), and in high and low prevalence centres; 2) compare phenotype characteristics, including clinical severity; 3) assess the risk factors for each phenotype; and 4) assess how the distribution of phenotypes differs between high prevalence and low prevalence centres. Here we present the rationale and protocol for the WASP study to enable other centres around the world to carry out similar analyses using a standardised protocol. Large collaborative and integrative studies like this are essential to further our understanding of asthma phenotypes. The findings of this study will help elucidate the aetiological mechanisms of asthma and might potentially identify new causes and guide the development of new treatments, thereby enabling better management and prevention of asthma in both HICs and LMICs.

Item Type: Article
Additional Information: Copyright ©ERS 2018. This article is open access and distributed under the terms of the Creative Commons Attribution Licence 4.0.
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: ERJ Open Res
ISSN: 2312-0541
Language: eng
Dates:
DateEvent
July 2018Published
22 August 2018Published Online
28 June 2018Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
205039/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
668954European Research Councilhttp://dx.doi.org/10.13039/501100000781
097834/Z/11/BWellcome Trusthttp://dx.doi.org/10.13039/100004440
102215/2/13/2Wellcome Trusthttp://dx.doi.org/10.13039/100004440
PubMed ID: 30151371
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/110120
Publisher's version: https://doi.org/10.1183/23120541.00013-2018

Actions (login required)

Edit Item Edit Item